Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cyclic Peptide Antiviral Agents and Methods Using Same

a technology of cyclic peptides and antiviral agents, applied in the direction of peptides, peptide/protein ingredients, immunoglobulins, etc., can solve the problems of weak potency and toxicity of existing entry inhibitors, and achieve the effects of reducing the risk of hiv-1 infection, promoting virolysis of a virus, and treating, reducing or preventing hiv-1 infection

Pending Publication Date: 2022-06-30
DREXEL UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This invention relates to a new chemical compound (Formula I), which can be used to treat HIV-1 infection. The compound can be made into a pharmaceutical composition and can help reduce the risk of HIV-1 infection or promote the destruction of the virus. This compound can also be used to modify gold nanoparticles. The technical effect of this patent is the discovery of a new chemical compound that can be used to develop new treatments and preventive measures for HIV-1 infection.

Problems solved by technology

Unfortunately, existing entry inhibitors suffer from weak potency and toxicity issues.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cyclic Peptide Antiviral Agents and Methods Using Same
  • Cyclic Peptide Antiviral Agents and Methods Using Same
  • Cyclic Peptide Antiviral Agents and Methods Using Same

Examples

Experimental program
Comparison scheme
Effect test

example 1

ptides

[0181]Cyclic peptides of the invention can be prepared using intramolecular cyclization according to the methods disclosed in International Application Publication No. WO 2016 / 094518, which is incorporated herein by reference in its entirety.

Chemical Synthesis of cPTs (3-38)

[0182]Alkynes a10-a16 were synthesized from the corresponding benzyl bromides a1-a9 following the procedures previously described (Louvel, et al., 2013, J. Med. Chem. 56:9427-40). Alkynes a10-a16 were used in click reactions without purification, because they are volatile and unstable upon storage. Mass validation of all cPTs was performed using Thermo Scientific LTQ XL Ion Trap LC / MS (Table 4).

General Synthesis of Alkynes a9-a16

[0183]To a solution of ethynyltrimethylsilane (40 mmol) in 20 mL THF at 0 ° C., was added i-PrMgCl (2 M solution in THF) dropwise, and the mixture was stirred at 0° C. for 30 min, and allowed to warm up to r.t. for 30 min. CuBr (6 mmol) was added, and the mixture was stirred at r.t....

example 2

us Production, Antiviral Assay and Cytotoxicity Assay

[0185]Pseudoviruses were produced as previously described (Umashankara, et al., 2010, ChemMedChem 5:1871-9). Briefly, HEK 293T cells (3×106) were co-transfected with 4 μg of BaL.01 gp160 plasmid and 8 μg of NL4-3R-E-Luc+ core DNA (obtained from the NIH AIDS Reagent Program), using Polyethyleneimine (PEI) as a transfection vehicle. After 72 hours, the supernatant containing virus was collected and filtered using a 0.45 μm syringe filter (Corning). The supernatant was then loaded on a 10 ml Iodixanol gradient; 6%-20% (Optiprep, Sigma Aldrich) and centrifuged on SW41Ti rotor (Beckman Coulter) at 30,000 RPM for 2 hours at 4° C. Virus samples were pooled from fractions 6 through 9 in 1 ml aliquots and diluted in serum free media, before storage in −80° C. All batches of virus were titrated for infectivity and p24 content immediately after production.

[0186]Pseudoviral infection assays were carried out as previously described (Emileh, et...

example 3

n of HIV-1 gp120 and Soluble CD4 Proteins Reagents

[0189]Escherichia coli strain Stbl2 cells were products of Novagen Inc. (Madison, Wis.). DNA plasmids encoding BaL.01 gp160 and NL4-3R-E-Luc+ were obtained from the NIH AIDS Reagent Program, Division of AIDS, NIAID. pcDNA3.1 vector carrying CD4 was a gift from Navid Madani. 17b IgG was purchased from Strategic Diagnostics Inc. (Newark, Del.). All other reagents used were of the highest analytical grade available.

Expression and Purification of Wild-Type gp120YU-2

[0190]The DNA for gp120YU-2 in pcDNA3.1 vector for transient transfection was purified using a Qiagen MaxiPrep kit (Qiagen) after transforming into Stbl2 competent cells. The purified DNA encoding gp120 YU-2 was transfected into HEK 293F cells according to manufacturer's protocol (Invitrogen). Five days after transfection was initiated, cells were harvested and spun down (3000 RPM), and the supernatant was filtered through 0.2 μm filters. Purification was performed over a 17b ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
MWaaaaaaaaaa
size distributionaaaaaaaaaa
Login to View More

Abstract

The present invention includes novel cyclic peptides, and methods of using the same. The present invention further includes novel cyclic peptides conjugated with a gold nanoparticle, and methods of using the same.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of U.S. patent application Ser. No. 16 / 331,861, filed Mar. 8, 2019, which is a 35 U.S.C. § 371 national phase application from, and claims priority to, International Application No. PCT / US2017 / 051380, filed Sep. 13, 2017, and published under PCT Article 21(2) in English, which claims priority to U.S. Provisional Patent Applications No. 62 / 394,494, filed Sep. 14, 2016, and No. 62 / 526,179, filed Jun. 28, 2017, all of which disclosures are incorporated herein by reference in their entireties.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT[0002]This invention was made with government support under GM056550 awarded by National Institutes of Health. The government has certain rights in the invention.BACKGROUND OF THE INVENTION[0003]The human immunodeficiency virus-1 (HIV-1) is responsible for a global epidemic, with over 33 million infected people worldwide. The lifecycle of HIV-1 has been exte...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K7/56A61K47/69A61P31/18
CPCC07K7/56A61K47/6929A61K38/00A61P31/18A61K47/6923A61K9/127C07K7/64A61K9/06A61K47/32C07K16/1063C07K2317/76
Inventor CHAIKEN, IRWIN M.AHMED, ADEL AHMED RASHAD
Owner DREXEL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com